Citi has maintained its 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) with a target price of £186, arguing that ...

AstraZeneca has been busy on the deal and research front, yet the more pressing question for you today is whether the current ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical ...

) has been revised to $202.76 / share. This is an increase of 107.33% from the prior estimate of $97.79 dated January 13, 2026. The price target is an average of many targets provided by analysts. The ...

Our AstraZeneca (NASDAQ:AZN) call comes one day after the British drugmaker reported Q1 2026 revenue of $15.29 billion, up 13% year over year, and reaffirmed full-year guidance. With shares at $185.20 ...

AstraZeneca PLC (AZN), the Cambridge, United Kingdom-headquartered Pharma giant with a market cap valuation just shy of $300bn at the time of writing (source: TradingView), announced its Q4 and ...

AstraZeneca PLC (NASDAQ:AZN) said on September 28 that it will make a $2 billion equity investment in Summit Therapeutics, ...

Stronger growth, oncology momentum, and deeper AI use support its innovation-led investment case.GSK: Higher income, solid ...

The average one-year price target for AstraZeneca PLC - Depositary Receipt (NasdaqGS:AZN) has been revised to $202.76 / share. This is an increase of 107.33% from the prior estimate of $97.79 dated ...